Stocks · News reference
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
Aehr Test Systems Insider Sells $847,000 Worth of Stock
Vernon Rogers, Executive VP of Sales & Marketing at Aehr Test Systems, sold 5,994 shares worth $847,000 at $141.34 per share. The sale represents only a 3% reduction in his direct holdings, with Rogers retaining 186,232 shares valued at $27.1 million. The transaction occurred after the stock surged 695% over the past 12 months, and analysts view this as routine profit-taking rather than a sign of concern about the company's future.
Shares of semiconductor and chip companies are trading lower, possibly after Federal Reserve Chairman Warsh's comments on inflation and prices raised rate-hike concerns. The sector may be facing pressure from peer Marvell Technology, as the company pulls back after its FY28 guidance may have failed to meet investor expectations.
Cardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology announced that Dr. Mani Mohindru will present at two upcoming conferences in September 2026, discussing the company's PLK1 inhibitor onvansertib for RAS-mutated metastatic colorectal cancer treatment. The company is advancing its lead asset through Phase 2 trials with positive data previously presented at ASCO.
William Blair Downgrades Cardiff Oncology to Market Perform
William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.